(Reuters) -The World Health Organization said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to ...

LONDON (Reuters) -Bavarian Nordic said on Thursday its mpox vaccine was approved by the EU's drug regulator for use in adolescents, bolstering the case for using the shot in the 12 to 17 age group ...

The first mpox vaccine approved by the WHO is MVA-BN, made by Bavarian Nordic A/S. It was approved for emergency use and can be used "off-label" in infants, children and adolescents as well as in ...

A clinical trial of an mpox vaccine in adolescents found it was safe and generated an antibody response equivalent to that seen in adults, according to a planned interim analysis of study data.

Bavarian Nordic's vaccine is currently only approved for people 18 years and older. "Children and adolescents are disproportionately affected by mpox in the ongoing outbreak in Africa ...

Bavarian Nordic A/S, one of the only companies with a vaccine approved for mpox, has received regulatory approval in Europe for the use of its jab for adolescents.. The European Commission ...

The vaccine was granted an Emergency Use Authorization for use in adolescents by the FDA during the 2022 global mpox outbreak. For More Such Health News, visit rttnews.com.

Bavarian Nordic shares on Friday surged once again as the mpox vaccine maker says it now is seeking approval to immunize adolescents. Bavarian Nordic is the only U.S. and European-approved vaccine ...

A National Institutes of Health (NIH)-funded clinical trial of an mpox vaccine in adolescents found it was safe and generated an antibody response equivalent to that seen in adults, according to a ...

Danish biotech company Bavarian Nordic said Friday that it had submitted data to the European Union's drug regulator to extend the use of its mpox vaccine for teenagers. CEO Paul Chaplin told CNBC ...

The vaccine during the 2022 mpox outbreak was granted emergency use authorization by the U.S. Food and Drug Administration for both pre- and post-exposure use in adolescents.